Danielle Antalffy
Stock Analyst at UBS
(3.68)
# 712
Out of 4,884 analysts
166
Total ratings
51.02%
Success rate
6.46%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMCI Treace Medical Concepts | Maintains: Neutral | $10 → $8.6 | $6.18 | +39.16% | 6 | May 9, 2025 | |
| ATRC AtriCure | Maintains: Buy | $60 → $58 | $31.76 | +82.62% | 13 | Apr 30, 2025 | |
| INMD InMode | Maintains: Neutral | $19 → $16 | $15.16 | +7.19% | 4 | Apr 29, 2025 | |
| RXST RxSight | Downgrades: Neutral | $45 → $16 | $13.05 | +22.61% | 3 | Apr 9, 2025 | |
| MDT Medtronic | Maintains: Neutral | $85 → $95 | $88.39 | +7.48% | 10 | Feb 19, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $105 → $130 | $104.32 | +24.62% | 12 | Feb 7, 2025 | |
| SGHT Sight Sciences | Maintains: Buy | $5.5 → $5 | $4.27 | +17.10% | 2 | Jan 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $146 → $148 | $134.44 | +10.09% | 12 | Jan 23, 2025 | |
| GKOS Glaukos | Initiates: Buy | $182 | $103.50 | +75.85% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $395.28 | -6.40% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $76.79 | -2.33% | 12 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $112 → $107 | $93.67 | +14.23% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $82.93 | +14.55% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $33.65 | +122.88% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $156.01 | +15.38% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $128.48 | +150.62% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $1.94 | +15.98% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $31.01 | +38.66% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $544.47 | -48.94% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $16.78 | +168.18% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $301.05 | -6.99% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $20.90 | +3,847.37% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $10.93 | +28.09% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $80.42 | +24.35% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $10.39 | +15.50% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $57.92 | -48.20% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $41.74 | +7.81% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $176.16 | +56.11% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $4.25 | +370.59% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $7.49 | +460.75% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.50 | +497.01% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.09 | +1,276.15% | 1 | Sep 1, 2020 |
Treace Medical Concepts
May 9, 2025
Maintains: Neutral
Price Target: $10 → $8.6
Current: $6.18
Upside: +39.16%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $58
Current: $31.76
Upside: +82.62%
InMode
Apr 29, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $15.16
Upside: +7.19%
RxSight
Apr 9, 2025
Downgrades: Neutral
Price Target: $45 → $16
Current: $13.05
Upside: +22.61%
Medtronic
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $88.39
Upside: +7.48%
Boston Scientific
Feb 7, 2025
Maintains: Buy
Price Target: $105 → $130
Current: $104.32
Upside: +24.62%
Sight Sciences
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $4.27
Upside: +17.10%
Abbott Laboratories
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $134.44
Upside: +10.09%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $103.50
Upside: +75.85%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $395.28
Upside: -6.40%
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $76.79
Upside: -2.33%
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $93.67
Upside: +14.23%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $82.93
Upside: +14.55%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $33.65
Upside: +122.88%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $156.01
Upside: +15.38%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $128.48
Upside: +150.62%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $1.94
Upside: +15.98%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $31.01
Upside: +38.66%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $544.47
Upside: -48.94%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $16.78
Upside: +168.18%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $301.05
Upside: -6.99%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $20.90
Upside: +3,847.37%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $10.93
Upside: +28.09%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $80.42
Upside: +24.35%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $10.39
Upside: +15.50%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $57.92
Upside: -48.20%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $41.74
Upside: +7.81%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $176.16
Upside: +56.11%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $4.25
Upside: +370.59%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $7.49
Upside: +460.75%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.50
Upside: +497.01%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $1.09
Upside: +1,276.15%